OSE Immunotherapeutics SA (OSE) is a biotechnology company that discovers and develops immune systems for immuno-oncology and immuno-inflammation. The company products include tedopi, OSE-279, FR104, BI 765063, OSE-230, BiCKI and CLEC-1. Its products treat NSCLC post-ICI, NSCLC combo 2L post-ICI, PDAC combo maintenance, OC mono and combo, solid tumor, lymphoma, kidney transplant, MSS endometrial, MSS CRC, inflammation diseases and immuno-oncology. OSE carries out clinical asset and pre-clinical platforms such as myeloid platform and BiCKI platform. The has collaborations and partnerships with pharmaceutical leaders, clinical organizations and academic laboratories. OSE is headquartered in Nantes, Pays-de-la-Loire, France.
Headquarters
France
Address
22, Boulevard Benoni Goullin, Nantes, Pays-de-la-Loire, 44200
Website
ose-immuno.com
Telephone
33 2 28291010
No of Employees
62
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
OSE (EPA)
Revenue (2022)
$2.4M
-87.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-29.5%
(2022 vs 2021)
Market Cap*
$130.8M
Net Profit Margin (2022)
XYZ
-964.5%
(2022 vs 2021)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| Products | Tedopi |
| Tedopi - NSCLC post-ICI, NSCLC Combo 2L post-ICI, PDAC Combo maintenance, OC Mono and Combo. | BiCKI |
| OSE-279- Solid Tumor and Lymphoma | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | OSE Immunotherapeutics SA | Ipsen SA | Innate Pharma SA | Genfit SA | NicOx SA |
|---|---|---|---|---|---|
| Headquarters | France | France | France | France | France |
| City | Nantes | Boulogne-Billancourt | Marseille | Loos | Valbonne |
| State/Province | Pays-de-la-Loire | Bourgogne | Bourgogne | Bretagne | Provence - Alpes- Cote d'Azur |
| No. of Employees | 62 | 5,325 | 179 | 159 | 11 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Nicolas Poirier | Director; Chief Executive Officer | Executive Board | - | - |
| Anne-Laure Autret-Cornet | Chief Financial Officer; Director | Executive Board | - | - |
| Sophie Fay | Chief External Affairs; Director | Executive Board | - | - |
| Jean-Jacques Mention | Chief Business Officer; Director | Executive Board | - | - |
| Dominique Costantini | Chief Development and Strategy; Director | Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer